Anavex Announces First Entire Clinical Alzheimer's Gene Pathway Data of ANAVEX®2-73 at AAIC 2022 (both Alzheimer's and Parkinson's disease)

benzinga.com/pressreleases/...

Expression levels of pathological dysregulated neurodegenerative genes of both Alzheimer's and Parkinson's disease were significantly restored by the therapeutic effect of ANAVEX®2-73 (p<0.005)

These findings will facilitate contextualization of upcoming readout of ANAVEX®2-73 Phase 2b/3 Alzheimer's disease clinical trial

[park_bear]

Poster referred to in the announcement –

79bcf7a1-8b8e-483b-b7cf-f5c...

Previous Presentation – extremely impressive results

static.seekingalpha.com/upl... ANAVEX®2-73 Improved MDS-UPDRS Total Score in Placebo-Controlled Parkinson’s Disease Dementia Phase 2 Study Estimated Difference between Active and Placebo: -14.51 points (p = 0.034) MDS-UPDRS Total Score ANAVEX2-73 high dose -10.98 Placebo 3.53